Glaukos Corporation (GKOS)
USD 145.14
(-0.83%)
USD 145.14
(-0.83%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -82.11 Million USD | 21.58% |
| 2022 | -48.76 Million USD | -58.9% |
| 2021 | -1.47 Million USD | 44.25% |
| 2020 | -83.58 Million USD | -148.99% |
| 2019 | -37.6 Million USD | -265.11% |
| 2018 | -6.1 Million USD | -28993.33% |
| 2017 | 5.9 Million USD | -99.12% |
| 2016 | 8.96 Million USD | 150.23% |
| 2015 | -32.95 Million USD | -14.29% |
| 2014 | -8.93 Million USD | 31.4% |
| 2013 | -12.75 Million USD | 39.29% |
| 2012 | -21.46 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -17.35 Million USD | -14.19% |
| 2024 Q2 | -19.54 Million USD | -10.9% |
| 2024 Q3 | -24.66 Million USD | 64.74% |
| 2023 Q3 | -27 Million USD | -24.84% |
| 2023 Q2 | -21.63 Million USD | -0.75% |
| 2023 FY | - USD | 21.58% |
| 2023 Q4 | -23.66 Million USD | 12.37% |
| 2023 Q1 | -21.47 Million USD | 22.62% |
| 2022 Q3 | -23.84 Million USD | 43.52% |
| 2022 Q4 | -27.75 Million USD | -16.37% |
| 2022 FY | - USD | -58.9% |
| 2022 Q1 | -12 Million USD | 36.21% |
| 2022 Q2 | -42.22 Million USD | -251.89% |
| 2021 Q2 | -5.46 Million USD | -23.73% |
| 2021 Q4 | -18.81 Million USD | 6.66% |
| 2021 Q3 | -20.15 Million USD | -269.14% |
| 2021 FY | - USD | 44.25% |
| 2021 Q1 | -4.41 Million USD | 46.57% |
| 2020 Q1 | -45 Million USD | -56.62% |
| 2020 Q2 | -44.18 Million USD | 1.82% |
| 2020 Q3 | -2.3 Million USD | 94.77% |
| 2020 Q4 | -8.26 Million USD | -257.73% |
| 2020 FY | - USD | -148.99% |
| 2019 Q4 | -28.73 Million USD | -178.02% |
| 2019 FY | - USD | -265.11% |
| 2019 Q3 | -10.33 Million USD | -97.86% |
| 2019 Q2 | -5.22 Million USD | -648.42% |
| 2019 Q1 | -698 Thousand USD | -136.79% |
| 2018 Q4 | 1.89 Million USD | 136.24% |
| 2018 FY | - USD | -28993.33% |
| 2018 Q2 | -4.24 Million USD | -311.23% |
| 2018 Q1 | -1.03 Million USD | -206.6% |
| 2018 Q3 | -5.23 Million USD | -23.23% |
| 2017 Q4 | 969 Thousand USD | -31.08% |
| 2017 FY | - USD | -99.12% |
| 2017 Q1 | 1.94 Million USD | 165.89% |
| 2017 Q2 | -3.26 Million USD | -267.62% |
| 2017 Q3 | 1.4 Million USD | 143.04% |
| 2016 FY | - USD | 150.23% |
| 2016 Q2 | 2.4 Million USD | 15.88% |
| 2016 Q3 | 1.34 Million USD | -44.19% |
| 2016 Q1 | 2.07 Million USD | 207.5% |
| 2016 Q4 | 733 Thousand USD | -45.46% |
| 2015 FY | - USD | -14.29% |
| 2015 Q4 | -1.93 Million USD | -12.71% |
| 2015 Q3 | -1.71 Million USD | 60.21% |
| 2015 Q2 | -4.31 Million USD | -3714.16% |
| 2015 Q1 | -113 Thousand USD | 97.14% |
| 2014 Q2 | -1.19 Million USD | 59.87% |
| 2014 Q3 | -825 Thousand USD | 30.73% |
| 2014 Q1 | -2.96 Million USD | 0.79% |
| 2014 Q4 | -3.95 Million USD | -379.03% |
| 2014 FY | - USD | 31.4% |
| 2013 Q3 | -2.99 Million USD | 3.78% |
| 2013 Q1 | -3.94 Million USD | 0.0% |
| 2013 Q2 | -3.1 Million USD | 21.27% |
| 2013 Q4 | -2.99 Million USD | 0.0% |
| 2013 FY | - USD | 39.29% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott Laboratories | 10.46 Billion USD | 100.785% |
| Allurion Technologies Inc. | -69.03 Million USD | -18.955% |
| Artivion, Inc. | 38.14 Million USD | 315.29% |
| Avanos Medical, Inc. | 53.2 Million USD | 254.353% |
| Butterfly Network, Inc. | -124.84 Million USD | 34.225% |
| Butterfly Network, Inc. | -124.84 Million USD | 34.225% |
| Bio-Rad Laboratories, Inc. | -608.26 Million USD | 86.5% |
| Boston Scientific Corporation | 3.45 Billion USD | 102.378% |
| Perspective Therapeutics, Inc. | -14.83 Million USD | -453.417% |
| CONMED Corporation | 182.18 Million USD | 145.073% |
| Edwards Lifesciences Corporation | 1.76 Billion USD | 104.646% |
| Paragon 28, Inc. | -36.61 Million USD | -124.275% |
| Globus Medical, Inc. | 418.23 Million USD | 119.634% |
| Inspire Medical Systems, Inc. | -17.06 Million USD | -381.336% |
| Integer Holdings Corporation | 282.05 Million USD | 129.113% |
| Medtronic plc | 9.05 Billion USD | 100.907% |
| Nevro Corp. | -78.31 Million USD | -4.86% |
| Owlet, Inc. | -27.48 Million USD | -198.723% |
| Penumbra, Inc. | 111.99 Million USD | 173.32% |
| Vicarious Surgical Inc. | -69.19 Million USD | -18.678% |
| Smith & Nephew plc | 979 Million USD | 108.388% |
| Sonendo, Inc. | -54.76 Million USD | -49.934% |
| STERIS plc | 1.41 Billion USD | 105.814% |
| Stryker Corporation | 5.16 Billion USD | 101.591% |
| Vapotherm, Inc. | -34.35 Million USD | -139.008% |
| Zimmer Biomet Holdings, Inc. | 2.44 Billion USD | 103.353% |